Literature DB >> 22189537

Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact.

Sofie Biering-Sørensen1, Peter Aaby, Bitiguida Mutna Napirna, Adam Roth, Henrik Ravn, Amabelia Rodrigues, Hilton Whittle, Christine Stabell Benn.   

Abstract

A total of 105 low-birth-weight children presenting for first vaccination were randomized to receive bacillus Calmette-Guérin (BCG) immediately or later (current practice). The mortality rate ratio for BCG was 0.17 (95% CI = 0.02-1.35) within 3 days of enrollment, 0.28 (0.06-1.37) in the first month, and 0.27 (0.07-0.98) after 2 months of age. The mortality rate ratio was 0.41 (0.14-1.18) (P = 0.098) in infancy. Administration of BCG vaccine at first contact may contribute to lower mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22189537     DOI: 10.1097/INF.0b013e3182458289

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  100 in total

1.  BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.

Authors:  Melanie A Gasper; Anneke C Hesseling; Isaac Mohar; Landon Myer; Tali Azenkot; Jo-Ann S Passmore; Willem Hanekom; Mark F Cotton; I Nicholas Crispe; Donald L Sodora; Heather B Jaspan
Journal:  JCI Insight       Date:  2017-04-06

Review 2.  Sex-based differences in immune function and responses to vaccination.

Authors:  Sabra L Klein; Ian Marriott; Eleanor N Fish
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-01       Impact factor: 2.184

3.  The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.

Authors:  Giuseppe La Torre; Rosella Saulle; Brigid Unim; Angela Meggiolaro; Angelo Barbato; Alice Mannocci; Antonietta Spadea
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

4.  Saving lives by training innate immunity with bacille Calmette-Guerin vaccine.

Authors:  Peter Aaby; Christine Stabell Benn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

5.  Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges.

Authors:  Peter Aaby; Tobias R Kollmann; Christine Stabell Benn
Journal:  Nat Immunol       Date:  2014-10       Impact factor: 25.606

Review 6.  Trained immunity and host-pathogen interactions.

Authors:  Adeline Peignier; Dane Parker
Journal:  Cell Microbiol       Date:  2020-09-17       Impact factor: 3.715

7.  Risk of Nontargeted Infectious Disease Hospitalizations Among US Children Following Inactivated and Live Vaccines, 2005-2014.

Authors:  Barbara H Bardenheier; Michael M McNeil; A Patricia Wodi; Janet M McNicholl; Frank DeStefano
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

8.  Association Between Bacillus Calmette-Guérin Vaccination and Childhood Asthma in the Quebec Birth Cohort on Immunity and Health.

Authors:  Mariam El-Zein; Florence Conus; Andrea Benedetti; Dick Menzies; Marie-Elise Parent; Marie-Claude Rousseau
Journal:  Am J Epidemiol       Date:  2017-08-01       Impact factor: 4.897

9.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.

Authors:  Magali Noval Rivas; Joseph E Ebinger; Min Wu; Nancy Sun; Jonathan Braun; Kimia Sobhani; Jennifer E Van Eyk; Susan Cheng; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

10.  Circadian rhythm influences induction of trained immunity by BCG vaccination.

Authors:  L Charlotte J de Bree; Vera P Mourits; Valerie Acm Koeken; Simone Jcfm Moorlag; Robine Janssen; Lukas Folkman; Daniele Barreca; Thomas Krausgruber; Victoria Fife-Gernedl; Boris Novakovic; Rob Jw Arts; Helga Dijkstra; Heidi Lemmers; Christoph Bock; Leo Ab Joosten; Reinout van Crevel; Christine S Benn; Mihai G Netea
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.